首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Activities of a Nitrofurazone-Containing Urinary Catheter and a Silver Hydrogel Catheter against Multidrug-Resistant Bacteria Characteristic of Catheter-Associated Urinary Tract Infection
【2h】

Activities of a Nitrofurazone-Containing Urinary Catheter and a Silver Hydrogel Catheter against Multidrug-Resistant Bacteria Characteristic of Catheter-Associated Urinary Tract Infection

机译:含氮呋喃酮的尿道导管和银水凝胶导管对与导管相关的尿路感染的多药耐药细菌特征的活性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The in vitro inhibitory activity of a nitrofurazone-coated urinary catheter (NFC) against 86 recently obtained susceptible and multidrug-resistant (MDR) clinical isolates of Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Staphylococcus aureus, coagulase-negative staphylococci, and Enterococcus faecium, which are species implicated in catheter-associated urinary tract infection and which traditionally have been susceptible to nitrofuran derivatives, was determined using an agar diffusion assay. In a subset of these strains, the activity of the NFC was compared with that of a silver hydrogel urinary catheter (SHC), and the durability of each catheter’s inhibitory activity was assessed during serial daily transfers of catheter segments to fresh culture plates. Except for vancomycin-resistant E. faecium, the NFC was active against all isolates tested and showed comparable inhibition zones with susceptible and MDR strains of each species. In contrast, the SHC inhibited only certain staphylococci (P < 0.01 versus the NFC), and among these strains, the SHC produced smaller inhibition zones than did the NFC (P < 0.01). Inhibition was evident for up to 5 days with the NFC, but for only 1 day (if at all) with the SHC (P < 0.01). These data document that, for most genera which traditionally have been susceptible to nitrofuran derivatives, the NFC remains active against contemporary MDR isolates. They also demonstrate that the in vitro antibacterial activity of the NFC is markedly superior to that of the SHC in several respects. Thus, the NFC shows promise for clinical use in the current era of MDR bacteria.
机译:硝基呋喃酮涂层导尿管(NFC)对最近获得的86株大肠杆菌,肺炎克雷伯菌,弗氏柠檬酸杆菌,金黄色葡萄球菌,凝固酶阴性葡萄球菌和肠球菌的易感和多药耐药(MDR)临床分离株的体外抑制活性使用琼脂扩散测定法确定了这些细菌,这些细菌与导管相关的尿路感染有关,并且传统上对硝基呋喃衍生物敏感。在这些菌株的一部分中,将NFC的活性与银水凝胶导尿管(SHC)的活性进行了比较,并在每天将导管片段连续转移到新鲜培养板上的过程中评估了每个导管的抑制活性的持久性。除了耐万古霉素的粪肠球菌外,NFC对所有测试的分离物均具有活性,并且对每种物种的敏感和耐多药菌株均显示出相当的抑制区。相反,SHC仅抑制某些葡萄球菌(与NFC相比,P <0.01),在这些菌株中,SHC产生的抑制区比NFC小(P <0.01)。 NFC可以抑制多达5天,而SHC则只能抑制1天(如果有的话)(P <0.01)。这些数据表明,对于传统上易受硝基呋喃衍生物影响的大多数属,NFC仍然具有对抗当代MDR分离物的活性。他们还证明,NFC的体外抗菌活性在几个方面明显优于SHC。因此,NFC显示出在当前MDR细菌时代临床应用的希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号